Cellyan Biotechnology (HKPD) Cash & Current Investments (2024 - 2025)
Cellyan Biotechnology (HKPD) reported Cash & Current Investments of $2.5 million for Q3 2025, up 579.09% year-over-year from $365391.0 in Q3 2024, and down 17.44% quarter-over-quarter from $3.0 million in Q1 2025.
Cellyan Biotechnology (HKPD) Cash & Current Investments (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Cash & Current Investments data on file, last reported at $2.5 million in Q3 2025.
- Cash & Current Investments for Q3 2025 came in at $2.5 million, up 579.09% year-over-year; the trailing twelve-month figure through Sep 2025 was $2.5 million (up 579.09% YoY), and the FY2025 annual result was $3.0 million, up 379.16% from the prior year.
- Cash & Current Investments declined to $2.5 million in Q3 2025 per HKPD's latest filing, from $3.0 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $3.0 million in Q1 2025 and troughed at $365391.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | 176.23 Mn |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | 3.98 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | 2.18 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | 3.94 Bn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | 138.00 Mn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | 336.88 Mn |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | 15.00 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | 79.14 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | 2.16 Mn |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - | 2.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.48 Mn |
| Mar 31, 2025 | 3.01 Mn |
| Sep 30, 2024 | 365,391.00 |
| Mar 31, 2024 | 627,257.00 |